Research Group of Dr. Elric Zweck

Main Research Topics
• Mitochondrial metabolism in cardiometabolic disease, including diabetes- and prediabetes-related, ischemic and non-ischemic heart failure.
• Quantitative methods for outcome prediction and phenotyping of cardiovascular disease, specifically in cardiogenic shock, mitral regurgitation and heart transplantation.
Current Projects
• Role of ketone bodies as mitochondrial substrates in cardiometabolic disease (funded by German Diabetes Society)
• Adaptations of mitochondrial substrate utilization in heart failure and type 2 diabetes mellitus (funded through FUTURE4CSPMM program by DFG grant no. 493659010)
• Maladaptation of cardiac mitochondrial metabolism to chronic ischemia in the diabetic human heart (funded by DFG grant no. 527448911)
Leading Team
Current dotoral and masters students
- Tobias Kunzelmann, Cand. med.
- Sina Kaufmann, Cand. med.
- Johannes Schmidt, Cand. med.
- Rosalie Eckl, Cand. med.
- Philipp Gabert, Cand. med.
- Minh Do Trong, Cand. med.
- Jana Lübbers, B. Sc.
- Digila Elisabath Francis, B. Sc.
Collaborations
• Navin K. Kapur, Tufts Medical Center, Boston, MA, USA
• Prof. Murray Mittleman, Harvard T. H. Chan School of Public Health, Boston, MA, USA
• Jacob E. Møller, Odense University Hospital and University of Southern Denmark, Denmark
Selected Publications
- Zweck E, Hassager C, Beske RP, Jensen LO, Eiskjaer H, Mangner N, Polzin A, Schulze PC, Skurk C, Nordbeck P, Clemmensen P, Panoulas V, Zimmer S, Schäfer A, Kelm M, Engstrom T, Holmvang L, Junker A, Schmidt H, Terkelsen CJ, Linke A, Westenfeld R, Moller JE: Microaxial Flow Pump Use and Renal Outcomes in Infarct-Related Cardiogenic Shock – a Secondary Analysis of the DanGer Shock Trial. Circulation. 2024. Epub ahead of print.
- Zweck E, Kanwar M, Li S, Sinha SS, Garan AR, Hernandez-Montfort J, Zhang Y, Li B, Baca P, Dieng F, Harwani NM, Abraham J, Hickey G, Nathan S, Wencker D, Hall S, Schwartzman A, Khalife W, Mahr C, Kim JH, Vorovich E, Whitehead EH, Blumer V, Westenfeld R, Burkhoff D, Kapur NK: Clinical Course of Patients in Cardiogenic Shock Stratified by Phenotype. JACC Heart Fail. 2023 Oct;11(10):1304-1315. doi: 10.1016/j.jchf.2023.05.007. Epub 2023 Jun 21. Impact factor in the year of publication (IF): 12.5
- Zweck E, Westenfeld R: Dapagliflozin in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2023 Jan;388(3):286. doi: 10.1056/NEJMc2213974. IF: 158.5
- Zweck E, Scheiber D, Schultheiss HP, Kuss O, Kelm M, Roden M, Westenfeld R, Szendroedi J: Impaired Myocardial Mitochondrial Respiration in Humans with Prediabetes – a Footprint of Prediabetic Cardiomyopathy. Circulation. 2022 Oct 11;146(15):1189-1191. Epub 2022 Oct 10. IF: 39.9
- Zweck E, Machine Learning identifies Clinical Parameters to predict Mortality in Patients Undergoing Transcatheter Mitral Valve Repair. JACC Cardiovasc Interv. 2021 Sep 27;14(18):2027-2036. IF: 11.2
- Zweck E, Thayer KL, Helgestad OKL, Kanwar M, Ayouty M, Garan AR, Hernandez-Montfort J, Mahr C, Wencker D, Sinha SS, Vorovich E, Abraham J, O‘Neill W, Li S, Hickey GW, Josiassen J, Hassager C, Jensen LO, Holmvang L, Schmidt H, Ravn HB, Moller JE, Burkhoff D, Kapur NK: Phenotyping Cardiogenic Shock. J Am Heart Assoc. 2021 Jul 20;10(14):e020085. IF: 5.5
- Zweck E*, Scheiber D*, Jelenik T, Bonner F, Horn P, Pesta D, Schultheiss HP, Boeken U, Akhyari P, Lichtenberg A, Kelm M, Roden M, Westenfeld R, Szendroedi J: Exposure to Type 2 Diabetes Provokes Mitochondrial Impairment in Healthy Human Hearts. Diabetes Care. 2021 May;44(5):e82-e84. IF: 16
- Swain L, Reyelt L, Bhave S, Qiao X, Thomas CJ, Zweck E, Crowley P, Boggins C, Esposito M, Chin M, Karas RH, O’Neill W, Kapur NK: Transvalvular Ventricular Unloading Before Reperfusion in Acute Myocardial Infarction. J Am Coll Cardiol. 2020 Aug, 76(6): 684-699. IF: 20.6
- Zweck E, Westenfeld R, Szendroedi J: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med. 2019 Nov;381(21):2075-2076. IF: 70.7
- Zweck E, Roden M: GLP-1 receptor agonists and cardiovascular disease: drug-specific or class effects? Lancet Diabetes Endocrinol. 2019 Feb;7(2):89-90. IF: 24.5